BamSEC and AlphaSense Join Forces
Learn More

Tandem Diabetes Care Inc.

NASDAQ: TNDM    
Share price (9/12/25): $12.27    
Market cap (9/12/25): $829 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 3 pages First Amendment to Settlement, Mutual Release and Cross-License Agreement
12/34/56
EX-10.1
from 10-Q 11 pages Settlement, Mutual Release and Cross-License Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Non-Employee Director Compensation Policy Adopted and Approved February 19, 2025
12/34/56
EX-10.29
from 10-K 2 pages Tandem Diabetes Care, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.28
from 10-K 5 pages Amendment No. 2 to Distributor Agreement Unomedical a/S and Tandem Diabetes Care, Inc. [***]: Certain Confidential Portions of This Exhibit Were Omitted by Means of Marking Such Portions With Asterisks Because the Identified Confidential Portions (I) Are Not Material, and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.26
from 10-K 8 pages Employment Severance Agreement
12/34/56
EX-10.5
from 10-Q 6 pages Amendment No. 1 to Distributor Agreement Unomedical a/S and Tandem Diabetes Care, Inc. Whereas A.COMPANY and Distributor Have Entered Into a Distributor Agreement Dated 14 January, 2022 (The “Agreement”); B.THE Parties Now Wish to Make Certain Amendments and Updates to the Agreement; as Such, the Parties Agree to Amend the Agreement as Set Forth Below: 1. Definitions the Definition of “Products” Is Deleted in Its Entirety and Amended and Restated as Follows
12/34/56
EX-10.4
from 10-Q 7 pages Employment Severance Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Material contract
12/34/56
EX-10.2
from 10-Q 39 pages Amended and Restated Commercialization Agreement
12/34/56
EX-10.1
from 10-Q 27 pages Amended and Restated Development Agreement
12/34/56
EX-10.1
from 8-K 28 pages [Dealer Name and Address] Tandem Diabetes Care, Inc. 12400 High Bluff Drive San Diego, California 92130 [Dealer] [Base][additional] Capped Call Transaction [ ], 2024 Dear Ladies and Gentlemen
12/34/56
EX-10.25
from 10-K 3 pages 10/31/2023 Mark Novara [Redacted]
12/34/56
EX-10.1
from 8-K 12 pages December 1, 2023 David Berger [Redacted] Re: Transition and Consulting Agreement (“Agreement”) Dear David: This Letter Sets Forth the Substance of the Transition and Consulting Agreement (The “Agreement”) That Tandem Diabetes Care, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition
12/34/56
EX-10.1
from 8-K 7 pages August 17, 2023 Brian Hansen [Redacted] Re: Separation Agreement (“Agreement”) Dear Brian
12/34/56
EX-10.2
from 10-Q 12 pages Notice of Restricted Stock Unit Award Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan
12/34/56
EX-10.1
from 10-Q 20 pages Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan as Approved by the Board of Directors on April 7, 2023 Article 1. Purposes of the Plan
12/34/56
EX-10.1
from 10-Q 3 pages Tandem Diabetes Care, Inc. 2023 Sr. Management Cash Bonus Plan
12/34/56
EX-10.33
from 10-K 67 pages Share Purchase Agreement Dated as of December 10, 2022 by and Among
12/34/56
EX-10.2
from 10-Q 22 pages Confidential Intellectual Property Agreement
12/34/56